Effect of Vancomycin Minimal Inhibitory Concentration on the Outcome of Methicillin-Susceptible Staphylococcus aureus Endocarditis
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Staphylococcus aureus endocarditis has a high mortality rate. Vancomycin minimum inhibitory concentration (MIC) has been shown to affect the outcome of methicillin-resistant S. aureus bacteremia, and recent data point to a similar effect on methicillin-susceptible S. aureus bacteremia. We aimed to evaluate the effect of vancomycin MIC on left-sided S. aureus infective endocarditis (IE) treated with cloxacillin. METHODS: We analyzed a prospectively collected cohort of patients with IE in a single tertiary-care hospital. Vancomycin, daptomycin, and cloxacillin MIC was determined by E-test. S. aureus strains were categorized as low vancomycin MIC (<1.5 µg/mL) and high vancomycin MIC (≥1.5 µg/mL). The primary endpoint was in-hospital mortality. RESULTS: We analyzed 93 patients with left-sided IE treated with cloxacillin, of whom 53 (57%) had a vancomycin MIC < 1.5 µg/mL and 40 (43%) a vancomycin MIC ≥ 1.5 µg/mL. In-hospital mortality was 30% (n = 16/53) in patients with a low vancomycin MIC and 53% (n = 21/40) in those with a high vancomycin MIC (P = .03). No correlation was found between oxacillin MIC and vancomycin or daptomycin MIC. Logistic regression analysis showed that higher vancomycin MIC increased in-hospital mortality 3-fold (odds ratio, 3.1; 95% confidence interval, 1.2-8.2) after adjustment for age, year of diagnosis, septic complications, and nonseptic complicated endocarditis. CONCLUSIONS: Our results indicate that vancomycin MIC could be used to identify a subgroup of patients with methicillin-susceptible S. aureus IE at risk of higher mortality. The worse outcome of staphylococcal infections with a higher vancomycin MIC cannot be explained solely by suboptimal pharmacokinetics of antibiotics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, this association between higher vancomycin MIC in infecting MSSA and worse clinical outcomes among patients treated with antistaphylococcal penicillins (not vancomycin) was externally validated in a large cohort of patients with MSSA IE. 142”
Citations
Cites
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E., Angus, D., Cook, D., Cohen, J., Opal, S. M., Vincent, J.-L., & Ramsay, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050454.01978.3b · Cited by 5,995 · cited 1×
“Definitions Conference [13].”
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027 · cited 1×
“Definitions The diagnosis of confirmed endocarditis was based on the modified Duke criteria [12].”
MethodMurdoch, D. R. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2008.603 · Cited by 2,362 · cited 1×
“Staphylococcus aureus is the leading cause of infective endocarditis (IE) worldwide [1].”
BackgroundBaddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Bolger, A. F., Levison, M. E., Ferrieri, P., Gerber, M. A., Tani, L. Y., Gewitz, M. H., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.165564 · Cited by 1,707
Staphylococcus aureus Endocarditis: A Consequence of Medical Progress
Fowler, V. G., Miro, J. M., Hoen, B., Cabell, C. H., Abrutyn, E., Rubinstein, E., Corey, G. R., Spelman, D., Bradley, S. F., Barsic, B., et al. (2005) · JAMA · doi:10.1001/jama.293.24.3012 · Cited by 1,174
Hidayat, L. K., Hsu, D. I., Quist, R., Shriner, K. A., & Wong-Beringer, A. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.19.2138 · Cited by 860 · cited 2×
“and 1 meta-analysis have confirmed this association with MRSA bacteremia treated with vancomycin [4–6].”
BackgroundRybak, M. J., Lomaestro, B. M., Rotscahfer, J. C., Moellering, R. C., Craig, W. A., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · Clinical Infectious Diseases · doi:10.1086/600877 · Cited by 815 · cited 1×
“MRSA bacteremia with a vancomycin MIC of 2 μg/mL using a dose of vancomycin of 15 mg/kg/12 hours we would have trough concentrations and AUC/MIC ratio around 10 mg/L and 200, respectively [16], which is clearly under the ideal threshold of clinical efficacy, it is recommended to increase the vancomycin dose to achieve…”
MethodSoriano, A., Marco, F., Martinez, J. A., Pisos, E., Almela, M., Dimova, V. P., Alamo, D., Ortega, M., Lopez, J., & Mensa, J. (2008) · Clinical Infectious Diseases · doi:10.1086/524667 · Cited by 767 · cited 2×
“and 1 meta-analysis have confirmed this association with MRSA bacteremia treated with vancomycin [4–6].”
BackgroundSelf-citationvan Hal, S. J., Lodise, T. P., & Paterson, D. L. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir935 · Cited by 512
Miro, J. M., Anguera, I., Cabell, C. H., Chen, A. Y., Stafford, J. A., Corey, G. R., Olaison, L., Eykyn, S., Hoen, B., Abrutyn, E., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/431979 · Cited by 334
Cited by
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Holland, T. L., Baddour, L. M., Bayer, A. S., Hoen, B., Miro, J. M., & Fowler, V. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.59 · Cited by 406
Management Considerations in Infective Endocarditis: A Review
Wang, A., Gaca, J. G., & Chu, V. H. (2018) · JAMA · doi:10.1001/jama.2018.7596 · Cited by 368
Staphylococcus aureusbacteraemia and endocarditis – epidemiology and outcome: a review
Ásgeirsson, H., Thalme, A., & Weiland, O. (2017) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2017.1392039 · Cited by 163
“Long-term mortality after SAE is not very well described, but a 1-year mortality rate of 19–44% has been observed [65,110,113,178,179,181,182].”
BackgroundDiaz, R., Afreixo, V. M. A., Ramalheira, E., Rodrigues, C., & Gago, B. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.06.017 · Cited by 101
Galar, A., Weil, A. A., Dudzinski, D. M., Muñóz, P., & Siedner, M. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00041-18 · Cited by 103
Adhesion of bacteria to surfaces and biofilm formation on medical devices
Floyd, K. A., Eberly, A. R., & Hadjifrangiskou, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-08-100382-4.00003-4 · Cited by 89
Gudiol, F., Aguado, J. M., Almirante, B., Bouza, E., Cercenado, E., Domínguez, M. Á., Gasch, O., Lora-Tamayo, J., Miró, J. M., Palomar, M., et al. (2015) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2015.03.015 · Cited by 78
“If this cannot be done, either because of allergy or a high risk of sodium overload, ceftaroline, either alone (B-II) or combined with daptomycin (C-II) , or linezolid, alone (C-II) or associated with daptomycin (C-III) , may be valid alternatives”
Shorr, A. F., Zilberberg, M. D., Micek, S. T., & Kollef, M. H. (2014) · BMC Infectious Diseases · doi:10.1186/s12879-014-0572-6 · Cited by 56
Moise, P. A., Culshaw, D. L., Wong‐Beringer, A., Bensman, J., Lamp, K. C., Smith, W. J., Bauer, K. A. A., Goff, D. A., Adamson, R. T., Leuthner, K. D., et al. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.017 · Cited by 56
Fernández‐Hidalgo, N., Ribera, A., Larrosa, N., Viedma, E., Origüen, J., de Alarcón, A., Fariñas, M. C., Sáez, C., Peña, C., Múñez, E., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.12.002 · Cited by 52
Bacteremia due to Methicillin-Resistant Staphylococcus aureus
Holubar, M. K., Meng, L., & Deresinski, S. C. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2016.02.009 · Cited by 46
Emonet, S., Charles, P. G., Harbarth, S., Stewardson, A. J., Renzi, G., Uçkay, İ., Cherkaoui, A., Rougemont, M., & Schrenzel, J. (2016) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2016.07.022 · Cited by 38
“This is not related only to the use of vancomycin, as MSSA bacteraemiawith an elevatedMIC for vancomycin has poorer outcomes even when treated with b-lactam agents [1,6,7].”
BackgroundFalcone, M., Russo, A., & Venditti, M. (2015) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2015.02.012 · Cited by 41
“2) than controls after adjustment for age, year of diagnosis, septic complications, and nonseptic complicated endocarditis [36].”
BackgroundHidalgo-Tenorio, C., Gálvez-Acebal, J., Martínez‐Marcos, F. J., Plata, A., Lima, J. D. L. T., López-Cortés, L. E., Noureddine, M., Reguera, J. M., García, D. V., García, M. V., et al. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-4895-1 · Cited by 33
Critical Questions About Left-Sided Infective Endocarditis
Román, J. A. S., Vilacosta, I., López, J., & Sarriá, C. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.016 · Cited by 35
Impact of Vancomycin MIC on Treatment Outcomes in Invasive Staphylococcus aureus Infections
Song, K., Kim, M., Kim, C.-J., Cho, J. E., Choi, Y. J., Park, J. S., Ahn, S., Jang, H., Park, K., Jung, S., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01845-16 · Cited by 31
Intravenous Vancomycin Dosing in the Elderly: A Focus on Clinical Issues and Practical Application
Barber, K. E., Bell, A. M., Stover, K. R., & Wagner, J. L. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0420-z · Cited by 30
Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile
Henson, K. E. R., Levine, M. T., Wong, E. A. H., & Levine, D. P. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1068118 · Cited by 33
de la Mària, C. G., Cervera, C., Pericàs, J. M., Castañeda, X., Armero, Y., Soy, D., Almela, M., Ninot, S. P. I., Falces, C., Mestres, C. A., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125818 · Cited by 29
“Our group recently found the same association of high vancomycin MIC and left-sidedMSSA IE [26].”
BackgroundSelf-citationJuan, R. S., Viedma, E., Cháves, F., Lalueza, A., Fortün, J., Loza, E., Pujol, M., Ardanuy, C., Morales, I., de Cueto, M., et al. (2016) · Emerging infectious diseases · doi:10.3201/eid2206.151709 · Cited by 27
“, which included only patients with endocarditis caused by MSSA, MICs for daptomycin were not related to increased mortality rates (8).”
Aldman, M. H., Skovby, A., & Påhlman, L. I. (2017) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2017.1280617 · Cited by 25
“For example, SA isolates with a Vancomycin MIC>1.5mg/l were related with higher mortality in MSSA endocarditis not treated with Vancomycin [12].”
BackgroundMenzo, S. L., la Martire, G., Ceccarelli, G., & Venditti, M. (2015) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2015.044 · Cited by 20
Is reduced vancomycin susceptibility a factor associated with poor prognosis in MSSA bacteraemia?
López-Cortés, L. E., Velasco, C., Retamar, P., del Toro, M. D., Gálvez-Acebal, J., de Cueto, M., García, I., Caballero, F. J., Pascual, Á., & Rodríguez‐Baño, J. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv133 · Cited by 19
Diagnosis, treatment and prevention of infective endocarditis: Turkish consensus report-2019*
Yavuz, S. Ş., Akar, A. R., Aydoğdu, S., Deniz, D. B., Demir, H., Hazırolan, T., Ozatik, M. A., Özer, N., Sargın, M., Topçuoğlu, N., et al. (2020) · Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · doi:10.5543/tkda.2020.89689 · Cited by 25
Sex Differences in Characteristics of Patients with Infective Endocarditis: A Multicenter Study
Bhandari, R., Tiwari, S., Alexander, T., Annie, F., Kaleem, U., Irfan, A. B., Balla, S., Wiener, R. C., Cook, C. C. H., Nanjundappa, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123514 · Cited by 19
Martirosov, D. M., Bidell, M. R., Pai, M. P., Scheetz, M. H., Rosenkranz, S., & Lodise, T. P. (2017) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2017.03.008 · Cited by 20
“…data suggest that patients with BSIs due to methicillinsusceptible S. aureus (MSSA) with high vancomycin MIC values are also at an overall increased risk of treatment failure, even when treated with a beta-lactam antibiotic (Aguado et al., 2011; Holmes et al., 2013b; Cervera et al., 2014).”
BackgroundInfluentialRapti, V., Giannitsioti, E., Spernovasilis, N. A., Magiorakos, A.-P., & Poulakou, G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14062087 · Cited by 19
Falcón, R., Martínez, A., Albert, E., Madrid, S., Oltra, R., Giménez, E., Soriano‐Navarro, M., Vinuesa, V., Gozalbo, D., Gil, M. L., et al. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.01.014 · Cited by 15
Lee, S. O., Lee, S., Park, S., Lee, J. E., & Lee, S. H. (2019) · Infection and Chemotherapy · doi:10.3947/ic.2019.51.4.376 · Cited by 15
Gallardo-García, M. M., Sánchez-Espín, G., Georgieva, R. I., Ruiz‐Morales, J., Rodríguez–Bailón, I., González, V., & García-López, M. V. (2016) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-016-2603-2 · Cited by 15
Pericàs, J. M., Messina, J. A., Garcia-de-la-Maria, C., Park, L., Sharma‐Kuinkel, B. K., Marco, F., WRAY, D. W., Kanafani, Z. A., Carugati, M., Durante‐Mangoni, E., et al. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.01.017 · Cited by 14
“Seventeen of these strains were included in the Spanish cohort [5].”
BackgroundSelf-citationEmerging and re-emerging infectious disease in otorhinolaryngology
SCASSO, F., FERRARI, G., Vincentiis, G. C. D., Arosio, A. D., Bottero, S., CARRETTI, M., CIARDO, A., Cocuzza, S. G., COLOMBO, A., Conti, B., et al. (2018) · Acta Otorhinolaryngologica Italica · doi:10.14639/0392-100x-suppl.1-38-2018 · Cited by 14
Shoji, H., Maeda, M., Shirakura, T., Takuma, T., Ugajin, K., Fukuchi, K., Ishino, K., & Niki, Y. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.07.013 · Cited by 13
Chen, P., Chuang, Y., Wang, J., & Chang, S. (2015) · Medicine · doi:10.1097/md.0000000000000474 · Cited by 13
“3%) had vancomycin MIC>1 mg/L by agar dilution in our study.(35,36) Therefore, we were unable to assess the association between mortality and vancomycin MIC.”
MethodFalcón, R., Madrid, S., Tormo, N., Casañ, C., Albert, E., Gimeno, C., & Navarro, D. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ583 · Cited by 12
Yavuz, S. Ş., Akar, A., Aydoğdu, S., Berzeg-Deniz, D., Demir, H., Hazırolan, T., Özatık, M. A., Özer, N., Sarğın, M., Topçuoğlu, N., et al. (2020) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2020.01954 · Cited by 13
Card, K. J., Crozier, D., Durmaz, A., Gray, J., Creary, J., Stocks, A., Maltas, J., Bonomo, R. A., Burke, Z. D. C., & Scott, J. G. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2507962122 · Cited by 10
Hentzien, M., Strady, C., Vernet-Garnier, V., Servettaz, A., de Champs, C., Delmer, A. J., Bani‐Sadr, F., & N’Guyen, Y. (2017) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2017.1323346 · Cited by 8
“Vancomycin MIC could also have an impact on mortality during methicillin-susceptible SA (MSSA) bacteraemia [7,8].”
BackgroundCurrent and emerging pharmacotherapy for the treatment of infections following open-heart surgery
Giacobbe, D. R., Corcione, S., Salsano, A., Puente, F. D., Pinna, S. M., Rosa, F. G. D., Mikulska, M., Santini, F., & Viscoli, C. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1574753 · Cited by 9
“Two important drawbacks to be weighed when choosing glycopeptides for treating postoperative infections in cardiac surgery patients are the risk of nephrotoxicity and the possible reduced effectiveness in case of severe MRSA infections due to isolates with vancomycin MIC >1 mg/L (albeit still in the susceptibility ran…”
BackgroundBouiller, K., Laborde, C., Aho, S., Hocquet, D., Péchinot, A., Moing, V. L., Bertrand, X., Piroth, L., & Chirouze, C. (2018) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.12.028 · Cited by 9
García-de-la-Mària, C., Gasch, O., Cañas, M. A., García‐González, J., Marco, F., Meneses, M. H., Quintana, E., Ambrosioni, J., Falces, C., Tolosana, J. M., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf245 · Cited by 6
Self-citationThe Times They Are A-Changin’: New Antibacterials for Skin and Skin Structure Infections
Tran, M.-C. N., Naumovski, S., & Goldstein, E. J. C. (2015) · American Journal of Clinical Dermatology · doi:10.1007/s40257-015-0125-9 · Cited by 6
“outcomes with MSSA infections, then a wider range of patients will be candidates for the newer therapeutic agents [63].”
BackgroundPericàs, J. M., Cervera, C., García-de-la-Mària, C., Sharma‐Kuinkel, B. K., Gonzales, R., Moreno, A., Almela, M., Falces, C., Quintana, E., Fuster, D., et al. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01579-19 · Cited by 6
Self-citationShi, C., Ye, J., Xu, R., Jin, W., Xu, S., Teng, F., & Lin, N. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-040675 · Cited by 5
CURRENT DATA ABOUT THE AETIOLOGY AND TREATMENT OF INFECTIVE ENDOCARDITIS
Zaha, D. C. (2022) · FARMACIA · doi:10.31925/farmacia.2022.5.8 · Cited by 4
Крохичева, П. А., Goldberg, M. A., Рустамовна, Х. Д., Antonova, O. S., Akhmedova, S. A., Kirsanova, V. A., Sviridova, I. K., Sergeeva, N. S., Leonov, A. V., Baikin, A. S., et al. (2021) · Russian Journal of Inorganic Chemistry · doi:10.1134/s0036023621080118 · Cited by 4
Kaasch, A. J., Jung, N., Fätkenheuer, G., & Seifert, H. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu874 · Cited by 4
“Theoretically, 3 scenarios could explain higher mortality in this setting: (1) enhanced pathogenicity of MSSA strains with increased van-MICs; (2) decreased efficacy of standard treatment; or (3) the presence of patient-related risk factors associated with increased van-MIC values.”
BackgroundPhenotypic and Genotypic Diversity of Staphylococcus aureus Isolated from Livestock and Human
Shehata, A. A. E., Abdel-Ghani, A. E., & Abdullah, M. M. (2015) · Cited by 3
Matsumura, M., Horiuchi, K., Domae, K., & Higuchi, Y. (2023) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytad235 · Cited by 3
Ramos, J. R., Vidal, P., Díaz-Lamas, A. M., Reig-Valero, R., Roche‐Campo, F., del Valle-Ortiz, M., Nuvials, X., Piquer, M. O., Andaluz‐Ojeda, D., Tamayo-Lomas, L., et al. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-017-2970-3 · Cited by 3
Morales‐Cartagena, A. (2015) · World Journal of Clinical Infectious Diseases · doi:10.5495/wjcid.v5.i2.14 · Cited by 4
Vancomycin MICs and risk of complicated bacteremia by glycopeptide-susceptible Staphylococcus aureus
Falcón, R., Mateo, E. M., Oltra, R., Giménez, E., Albert, E., Torres, I., & Navarro, D. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03500-7 · Cited by 3
Sáez, C., Sarriá, C., Vilacosta, I., Olmos, C., López, J., García-Granja, P. E., Fernández, C., Cuevas, C. D. L., Reyes, G., Domínguez, L., et al. (2019) · Medicine · doi:10.1097/md.0000000000016903 · Cited by 3
Wang, J., Hu, J., Chen, Y., Li, S., Jm, P., Dong, R., Hu, X., Jiang, W., Wang, C., Weng, L., et al. (2026) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70235 · Cited by 2
“Despite its proven efficacy [3–6], optimal vancomycin use remains challenging due to the narrow therapeutic range [7].”
Microsphere Spray System for Wound Coverage
Andersen, N. J. (2014) · UKnowledge (University of Kentucky) · Cited by 2
Intravenous Antibiotics Used in the Treatment of Methicillin-Resistant Staphylococcus Aureus
Scordo, K. A. (2015) · AACN Advanced Critical Care · doi:10.1097/nci.0000000000000095 · Cited by 1
Infective Endocarditis in the Current Clinical Practice
Горбич, Ю. Л., Карпов, И. А., Соловей, Н. В., & Горбич, О. А. (2020) · Клиническая инфектология и паразитология · doi:10.34883/pi.2020.9.1.009 · Cited by 1
Cervera, C., de la Maria, C. G., Pericàs, J. M., Moreno, A., & Miró, J. M. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu875
Self-citationHolubar, M. K., Meng, L., & Deresinski, S. C. (2016)
Mubariz, R., Yasmin, S., Taj, S., Butt, T. M., Ellahi, A., & Mussarat, U. (2022) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v72i2.7083
Metadata
- Authors
- Cervera, C., Castaneda, X., de la Maria, C. G., del Rio, A., Moreno, A., Soy, D., Pericas, J. M., Falces, C., Armero, Y., Almela, M., Ninot, S., Pare, J. C., Mestres, C. A., Gatell, J. M., Marco, F., Miro, J. M., The Hospital Clinic Endocarditis Study Group, Miro, J. M., Moreno, A., del Rio, A., Cervera, C., Pericas, J. M., Castaneda, X., Gatell, J. M., Marco, F., Almela, M., Jimenez-de-Anta, M. T., de la Maria, C. G., Armero, Y., Mestres, C. A., Pare, J. C., Falces, C., Cartana, R., Ninot, S., Azqueta, M., Sitges, M., Heras, M., Pomar, J. L., Ramirez, J., Ribalta, T., Brunet, M., Soy, D., & Llopis, J.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03-18
- Volume
- 58
- Issue
- 12
- Pages
- 1668-1675
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2113688823
- Semantic Scholar
- 4f9f34df6f671ca460fe94e76c0b861a6421abe4
- Cited by
- 61
- References
- 25
- Citations by year
- 2026: 1 · 2025: 3 · 2023: 1 · 2022: 3 · 2021: 2 · 2020: 5 · 2019: 5 · 2018: 3 · 2017: 8 · 2016: 10 · 2015: 16 · 2014: 4
- FWCI
- 9.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Infectious Diseases › Streptococcal Infections and Treatments
- Keywords
- methicillin-susceptible Staphylococcus aureus, infective endocarditis, in-hospital mortality, cloxacillin, daptomycin, antibiotic susceptibility, left-sided endocarditis, septic complications
- MeSH terms
- Adult, Aged, Anti-Bacterial Agents, Cloxacillin, Endocarditis, Bacterial, Female, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Retrospective Studies, Staphylococcal Infections, Staphylococcus aureus, Vancomycin, Survival Rate, Hospital Mortality, Daptomycin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.